Overview

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics of buprenorphine and its metabolites in the presence and absence of ketoconazole.
Phase:
Phase 1
Details
Lead Sponsor:
Purdue Pharma LP
Treatments:
Buprenorphine
Ketoconazole